Xeraya Capital

GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Imago BioSciences is a clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives. Imago BioSciences was founded in 2012 and is based in Redwood City, California.

InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.

Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators.

Aria CV was founded in 2010 by Drs. John Scandurra and Karl Vollmers, formerly Fellows at the University of Minnesota’s Medical Devices Center. Aria has an exclusive license to certain patents from the University of Minnesota. Aria CV’s device has the potential to improve outcomes by reducing the workload on the right side of the heart.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.

Consumer Physics is driven by a mission to empower consumers and businesses to learn about the makeup of materials anytime, anywhere by using SCiO, the smallest near-infrared (NIR) spectrometer. The SCiO sensor pairs with SCiO smartphone apps and connects to a cloud-based database of material fingerprints. Consumer Physics offers businesses and 3rd party developers a platform that enables them to design their own molecular sensing models and mobile applications for personal and commercial use. The SCiO DevKit includes the SCiO Lab development platform and Mobile SDK and access to professional support from Consumer Physics experts.

P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These include flavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain.

Chrono Therapeutics (CHRONO) is a pharmaceutical company founded in 2004 with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery (TDD) that offers real-time behavioral support. Chrono’s executive leadership combines years of professional experience and personal passions for developing life-saving medical products. Steeped with years of experience in product development, science, R&D an understanding of the consumer smoking cessation market, FDA approval experience and bringing life-saving products to market, the team represents a wide-array of knowledge that combined can help address the serious epidemic of smoking.

ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals. It was founded in 2011 and headquartered in Carlsbad, California.

Boston Neurosciences Inc is a neurodiagnostics medical device company with offices in Boston, USA, and Kaunas, Lithuania. The company has developed a suite of ultrasound-based devices to non-invasively measure the absolute value of intracranial pressure (ICP), real-time cerebral blood flow autoregulation (CA), and intracranial volumetric wave monitoring. The non-invasive diagnostic methods have been clinically tested and proven in leading neuro centers in Europe and the United States.

ViewRay develops advanced radiation therapy technology for the treatment of cancer. It designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side effects from off-target radiation delivery. The company was incorporated in 2004 and is based in Cleveland, Ohio.

PrIME Biologics is a Singapore-based biotech company that has developed a disposable therapeutic plasma manufacturing process based on PrIME technology—Preparative Isolation by Membrane Electrophoresis. PrIME is pioneering this technique in its plasma manufacturing plant in Singapore to address the US$1 billion Asian plasma derivative market.

invendo medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology. Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendo medical´s goal is to improve patient compliance and thereby increase the number of procedures performed.

Gevo brings renewable and cost-effective fossil fuel alternatives to consumers worldwide will be absolutely essential to meet increasing energy demands and save their earth from global warming. Gevo focuses on the production of isobutanol.